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oligonucleotide arrays. Applying both an unsupervised hierarchical
clustering analysis and a supervised Bayesian ANOVA analysis, 300
genes from these analyses were classiﬁed as being either membrane
bound or soluble gene products based on the database of mem-
brane-associated/soluble gene products generated by Diehn et al.
(PLoS Genetics epub 2006). Thirty-two of these were annotated to
be secreted gene products. Several novel growth factors not typi-
cally associated with hematopoiesis were identiﬁed. We have found
that one of these factors, adrenomedullin, a vasodilator not known
to have hematopoietic function, induces the proliferation of human
BM CD34CD38-lin- HSCs in single cell cultures and promotes
the quantitative expansion of human BM CD34 progenitor cells
in vitro. This molecular signature of HUBECs provides a unique
resource for the discovery and characterization of novel soluble
factors that regulate human HSC fate.
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FLT3 EXPRESSION DISCRIMINATES HSC SUBPOPULATIONS WITH DIF-
FERING ENGRAFTMENT-POTENTIAL
Huang, Y.1, Ratajczak, M.Z.2, Reca, R.2, Xu, H.1, Tanner, M.1,
Rezzoug, F.1, Hussain, L.-R.1, Fugier-Vivier, I.1, Bolli, R.3,
Ildstad, S.T.1 1Institute for Cellular Therapeutics, Louisville, KY; 2Stem
Cell Biology Program, James Graham Brown Cancer Center, Louisville,
KY; 3Division of Cardiology, University of Louisville, Louisville, KY.
HSC, sorted as KSL (c-KitSca-1Lin-) cells, are comprised of
primitive long-term repopulating cells and short-term repopulat-
ing committed progenitors. Growth factors such as GM-CSF,
G-CSF or Flt3-ligand (FL) are utilized to expand and mobilize
HSC. We evaluated here the phenotype and function of FL-
mobilized HSC. FL signiﬁcantly expands c-Kithi and c-Kitlo KSL
cells in peripheral blood (PB). Only FL-expanded PB c-Kithi KSL
cells exhibited high spleen colony-forming unit frequency, gener-
ated high numbers of both lymphoid and myeloid colonies in vitro,
and rescued ablated recipients. FL expanded two subsets of c-Kithi
KSL cells: CD34ﬂt3- reﬂective of short-term HSC (ST-HSC)
and CD34-ﬂt3- long-term HSC (LT-HSC), while the proportion
of c-Kithi CD34ﬂt3 KSL cells multipotent progenitors (MPP)
was signiﬁcantly decreased in the PB. When 500 CD34ﬂt3-,
CD34ﬂt3 or CD34-ﬂt3- c-Kithi KSL cells were transplanted
into ablated syngeneic recipients, all recipients of CD34ﬂt3
c-Kithi KSL expired within 16 days (n 5). One of the 5 recipients
of c-Kithi CD34ﬂt3- KSL (ST-HSC) survived over 120 days. The
combination of 50 c-Kithi CD34-ﬂt3- KSL cells (LT-HSC) with
500 c-Kithi CD34ﬂt3- or CD34ﬂt3 KSL cells enhanced recip-
ient survival (4/6 recipients of both ST-HSC plus LT-HSC sur-
vived over 120 days and some recipients of MPP  LT-HSC
survived up to 68 days ). These data suggest that ﬂt3 expression
may be a useful phenotypic marker for selecting critical stem cell
populations to ensure rapid and durable engraftment and conﬁrms
that both short and long-term repopulating cells are needed for
optimal successful transplantation.
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ABILITY OF ANTI C-KIT TARGETING MONOCLONAL ANTIBODY ACK-2
TO TARGET HEMATOPOIETIC STEM CELLS, AND FACILITATE ENGRAFT-
MENT OF HUMAN CD34 ENGRAFTMENT AND HEMATOLYMPHOID
DEVELOPMENT IN IMMUNODEFICIENT MICE: A NOVEL ANTIBODY
BASED CONDITIONING STRATEGY
Kraft, D.L.1, Czechowicz, A.1, Bhattacharya, D.1, Weissman, I.L.1
1Stanford University School of Medicine, Stanford, CA.
INTRODUCTION: The stem cell receptor factor receptor,
c-Kit, is expressed on hematopoeitic stem (HSC) and progenitor
cell populations and may serve as a target molecule for manipula-
tion of host HSC & their niche. ACK2 is an anti-mouse c-Kit mAb
which has been shown to antagonize the function of c-kit and
deplete the bone marrow. We wished to characterize the effect &
kinetics of ACK2 on blood cell counts and marrow hematopoetic
stem cell (HSC) and progenitor populations. We also sought to
test the hypothesis that treatment with an HSC targeting mAb may
serve as an novel antibody based conditioning strategy as well as a
means for enhancing human HSC engraftment in immunodeﬁ-
cient mice by selectively inhibiting murine HSC.
METHODS: Adult C57/BL mice were injected with anti
1-500ug of ACK2 mAb & peripheral blood counts, as well as
marrow HSC and progenitor frequency were followed. Subse-
quently, we examined the ability of ACK2 to enhance human
engraftment in sublethally irradiated (4Gy) immunodeﬁcient
RAG2/Common Gamma-Chain double knock out (RAG2-DKO)
pups injected intrahepatically with 1-510^5 CD34 cells from
human mobilized peripheral blood (hCD34).
RESULTS: Administration of ACK2 resulted in rapid develop-
ment of anemia, neutropenia & thrombocytopenia. In treated
mice, the mean number & bone marrow fraction of Long-Term
HSC decreased markedly from .07% of total marrow cells in
controls to .003% in ACK2 treated mice as did the marrow num-
ber/frequency of CMP, GMP, and CMP. Human CD34 trans-
planted RAG-2 DKO mice treated with ACK2 engrafted at a
higher rate (46% vs 27% of controls achieved 10% human
chimerism) with higher human CD45 chimerism in blood, bone
marrow, spleen, liver, & lymph nodes. Robust human thymopoeisis
was observed with a mean of 63% of cells within the thymus
human derived. We found differentiation of mature human T-cells
occured via a CD3-48- intermediate a pathway identical to that
which we found in human stroma in SCID-hu T-cell development.
The ability for host ACK2 conditioning alone to enable donor
murine HSC engraftment will be presented.
CONCLUSIONS: Anti c-kit mAb treatment rapidly induces
pancytopenia with correlating decreases in the numbers of marrow
HSC and other progenitor populations and may serve as a strategy
for host HSC targeted mAb based conditioning. ACK-2 enhances
the frequency and degree of human CD34 engraftment and
human thymopoiesis and may serve as a means to enhance this new
model of human hematopoiesis.
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MUTATED HOXB4 RESULTS IN INCREASED INTRACELLULAR STABILITY
AFFECTING BOTH LONG AND SHORT TERM HEMATOPOIETIC RECON-
STITUTION
Beauchemin, S.1, Krosl, G.1, Nathalie, B.2, Krosl, J.2, Sauvageau, G.1,2,
Roy, D.C.1,2 1Hopital Maisonneuve-Rosemont Research Center, Mon-
treal, QC, Canada; 2Research Institute for Immunology and Cancer,
Montreal, QC, Canada.
The capacity of recombinant Hoxb4 protein to induce ex vivo
expansion of hematopoietic stem cells (HSCs) identiﬁes this pro-
tein as a potential HSC expanding factor. However, its short extra-
and intra-cellular half-life (3-4 hours and 40-60 minutes, respec-
tively) hampers clinical applications of Hoxb4. The analyses of
Hoxb4 molecular structure lead us to generate amino acid substi-
tutions: (A) Leu73Ala, (B) Tyr233Ala and (C) Tyr283Ala in
the Hoxb4 protein in order to promote its stability. Indeed, these
modiﬁcations increased the intracellular stability of Hoxb4 protein
3-fold compared to wild type Hoxb4 (Hoxb4(WT)). The ability
of mutated Hoxb4 protein to favor expansion of hematopoietic
progenitors was ﬁrst examined in cultures initiated with 10%
Hoxb4(WT)-GFP, 10% mutated Hoxb4-YFP expressing cells and
80% non-transduced cells. After an 18-day culture, the proportion
of A and B Hoxb4 mutants cells increased to 50-60% in compar-
ison to 30% for Hoxb4(WT) (p 0.05), and no difference between
the proliferation of C Hoxb4 mutant and Hoxb4(WT) cells could
be identiﬁed. Western blot analyses showed that the A and B
Hoxb4 mutants expressed  4-fold higher and C Hoxb4 mutant
cells  8-fold lower levels of Hoxb4 protein than Hoxb4(WT)
cells. The long-term reconstituting ability of these constructs was
then evaluated in vivo using competitive repopulation assays. At 8
and 16 weeks after transplantation, A and B Hoxb4 mutants con-
tributed less peripheral blood and BM leukocytes (PBL) than
Hoxb4(WT). Flow cytometry analysis of bone marrow, spleen and
thymus revealed that mutated Hoxb4, like Hoxb4(WT) was ex-
pressed by all hematopoietic lineages, and that repopulation dif-
ferences observed between mutated and WT Hoxb4 expressing
cells were almost entirely attributable to myeloid lineage cells.
However, non-competitive repopulation experiments showed that
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the A and B mutated Hoxb4 expressing progenitors had a signiﬁ-
cantly greater contribution to the PBL recovery in comparison to
Hoxb4(WT) (p  0.05). Together, these studies strongly suggest
that different intracellular levels of Hoxb4 protein are affecting
different types of hematopoietic progenitors. Early ex vivo expan-
sion of clonogenic progenitors was achieved with mutated Hoxb4
proteins without impairing HSC long-term reconstituting ability.
Thus, mutated Hoxb4 could represent a useful tool to accelerate
engraftment after HSC transplantation.
SUPPORTIVE CARE
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THE USE OF RECOMBINANT HUMAN ERYTHROPOIETIN (RHUEPO)
AFTER REDUCED INTENSITY CONDITIONING (RIC) ALLOGENEIC HE-
MATOPOIETIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION
(ASCT) REDUCES RED BLOOD CELL (RBC) TRANSFUSION REQUIRE-
MENTS
Ivanov, V.1, El Cheikh, J.1, Faucher, C.1, Furst, S.1, Mohty, M.1,
Ladaique, P.1, Lemarie, C.1, Charbonnier, A.1, Coso, D.1,
Schiano, J.M.1, Viret, F.1, Blaise, D.1 1Institut Paoli-Calmettes, Mar-
seille, France.
We previously reported that hemoglobin (Hb) recovery was
hastened after RIC ASCT as compared with ASCT after myeloa-
blative conditioning (Transfusion, 44:501-8, 2004). In this setting
pretransplant Hb level becomes the major predictive factor for
early Hb recovery posttransplant and RBC transfusion (RBCT)
requirements. We subsequently reported the efﬁcacy of early
rHuEpo administration after RIC ASCT to hasten Hb reconsti-
tution (BMT, 36:901-6, 2005). Here we further conﬁrm that early
post-transplant rHuEpo after RIC reduces also RBC requirements.
40 pts surviving at least 60 days were analyzed. Pts characteristics
were as follow: age: 50 (27-64); M/F: 28/12; with myeloid (4),
lymphoid (29) or solid (7) malignancies. They received a RIC
(Fludarabin (150 mg/m; Busulfan (8mg/kg) and thymoglobulin (2.5
to 5 mg/kg)) followed with an ASCT (all PBSC) from a HLA
identical sibling. Aranesp(Amgen, France) was started on day 1.
The 20 ﬁrst pts received an infusion of 150 mcg/week while the 20
last pts were subsequently treated with 500 mcg/ 3 weeks. Aranesp-
was administered intravenously when inpatient and subcutaneously
when outpatient. Aranespadministration was sustained until day 60
or when pts reached a Hb level of 140 g/L, whichever occurred
ﬁrst. Overall pts were treated for a median of 7 weeks post trans-
plant. No serious adverse effect or thrombosis episode was re-
ported. This cohort of 40 pts experienced a quicker Hb recovery
and lower RBCT requirements than a historical and comparable
control group of 27 pts (Day 30 Hb: 114 (94-141) vs. 100
(80-129), p.0001; pts with 0 or 1 RBCT: 83% vs. 55% (p.02)).
Thirteen of the 40 pts (33%) presented with an Hb level of 120 g/L
or more prior to conditioning. Over the ﬁrst 60 days, these pts
received 0 (0-2) RBCT as compared with 1 (0-2) RBCT for pts
with a pre-RIC Hb level  120 g/L (p.05). On this basis, we
hypothesized the interest of increasing Hb level prior to RIC by
adequate rHuEpo stimulation. With this perspective, we have
treated 13 pts with Aranesp(500 mcg, SC) 3 weeks prior RIC. Nine
of these 13 pts (69%) reached an Hb level of 120 g/L or more on
day -7 as compared to 35% in patients not receiving Aranesp prior
to RIC (p.04). This indicates that Aranesppost RIC ASCT is
efﬁcient to hasten Hb recovery and decrease RBCTs. In addition,
a comprehensive strategy to minimize RBCT in this setting might
include pre-transplant stimulation. We will prospectively assess
this hypothesis.
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PROSPECTIVE ORAL MUCOSITIS AUDIT (POMA): OCCURRENCE AND
CONSEQUENCES OF SEVERE ORAL MUCOSITIS IN HIGH DOSE MELPHA-
LAN AND BEAM CONDITIONING
Blijlevens, N.1, McCann, S.2, Bacon, P.3, Quinn, B.4,
Schwenkglenks, M.5, Stone, R.6, Pico, J.7 1University Medical Centre St
Radboud, Nijmegen, Netherlands; 2St. James Hospital, Dublin, Ireland;
3Amgen International, Zug, Switzerland; 4Royal Marsden School of
Cancer Nursing and Rehabilitation, London, United Kingdom; 5Uni-
versity Hospital, Basel, Switzerland; 6Nottingham City Hospital NHS
Trust, Nottingham, United Kingdom; 7Amgen, Paris, France.
Oral mucositis (OM), an adverse effect of myeloablative reg-
imens, seriously affects patient well-being and may increase
systemic infection risk and delay recovery. Trial-based reports
of OM vary widely, with evidence of underreporting and limited
data on the incidence and impact in routine practice. Initiated
by the EGBMT, this study observed pts with multiple myeloma
(MM) or non-Hodgkin’s lymphoma (NHL) from 25 transplant
centres across 13 EU countries receiving high dose melphalan
or BEAM then autologous stem-cell transplant. Aims were to
assess duration and incidence of severe (WHO oral toxicity scale
Grade III-IV) and ulcerative (Grade II-IV) OM, resource use
for OM prevention and treatment, and associations with infec-
tion and hospitalisation duration. Prospective OM assessments
were done daily from the conditioning start to 30 days post-
transplant or hospital discharge. To achieve high and consistent
quality of assessment, nurse assessors had multimedia-assisted
face-to-face training prestudy. Of 197 evaluable pts, 110 (56%)
had MM and 87 (44%) had NHL. Mean age was 578 yrs for
MM (36% women) and 5013 yrs for NHL (51% women); 94%
had ECOG status 1. Severe OM incidence was 46% (95% CI
37-56%) for MM and 41% (95% CI 31-52%) for NHL. Severe
OM mean duration was 5.43.3d (95% CI 4.6-6.3d) in MM and
5.33.2d (95% CI 4.3-6.4d) in NHL. Ulcerative OM incidence
was 67% (95% CI 58-76%) in MM and 60% (95% CI 49-70%)
in NHL (mean duration 6.64.4d [95% CI 5.6-7.6d] and
6.53.8d [95% CI 5.6-7.7d]). WHO scale results and symptom
indicators showed similar temporal patterns (max  day 12
post-conditioning) in both groups. Clinically relevant associa-
tions with disease/conditioning type or gender were not de-
tected. A non-signiﬁcant trend hinted at an association of OM
duration with age. Fever 38°C incidence was 68% in pts with
severe OM v 47% in pts without (univariate p.004; odds ratio
2.4 [95% CI 1.3-4.4]). Mean length of staySD (truncated at
30d posttransplant) was 214d in pts with severe OM v 205d
in pts without (univariate p.023). Preliminary multivariate
analyses adjusting for other potential predictors conﬁrmed these
effects. Severe OM was a substantial clinical problem with high
dose melphalan or BEAM conditioning chemotherapy. Associ-
ations with fever occurrence and length of stay indicate poten-
tially harmful clinical sequelae and economic consequences.
Associations with conﬁrmed infection and resource use remain
to be assessed.
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COST ANALYSIS OF ALLOGENIC PERIPHERAL BLOOD TRANSPLANTA-
TION: IMPACT OF DEGREE OF MUCOSITIS AND USAGE OF PALIFERMIN
Dooley, M.J.1, Schwarer, A.1, Poole, S.G.1, Radhakrishnan, M.1,
Farag, S.1, Neville, M.2, Lee, J.2 1The Alfred, Melbourne, Victoria,
Australia; 2Pretium Pty Ltd, Sydney, New South Wales, Australia.
Background: Oral mucositis is associated with increased clinical
events and healthcare resource utilization in patients receiving
hematologic stem cell transplantation (HSCT) following myleoa-
blative therapy. Palifermin is a recombinant human keratinocyte
growth factor approved to prevent severe oral mucositis. The
impact of palifermin in the allogenic peripheral blood (PBSCT)
and the costs associated has not been quantiﬁed.
Aim: To assess the clinical and economic impact of palifermin
use in allogeneic HSCT patients.
Method:
This was a retrospective review of 21 patients undergoing allo-
genic HSCT following myeloablative chemotherapy at The Alfred
from June 2004-October 2005; versus allogeneic HSCT patients
receiving palifermin from October 2005-July 2006. We calculated
descriptive statistics on duration and grade of oral mucositis; hos-
pital length of stay (LOS), antibiotic use; antifungal use; and total
parenteral nutrition (TPN). Costs were determined through data
extracts from the hospital’s clinical costing system and through
retrospective medical record review.
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